Home > Insider Trading > Filing (0001209191-12-041041)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1012140	Onyx Pharmaceuticals Inc	ONXX	Biological Products, (No Disgnostic Substances) (2836)	943154463

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1312622	I Kaye Foster-Cheek	C/O Onyx Pharmaceuticals, Inc. 249 East Grand Ave. South San Francisco CA 94080	Svp, Global Human Resources	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2012-08-06	9,333	$35.18	52,907	No	4	M	Direct
Common Stock	Acquisiton	2012-08-06	12,708	$26.38	65,615	No	4	M	Direct
Common Stock	Disposition	2012-08-06	22,041	$70.44	43,574	No	4	S	Direct
Common Stock	Disposition	2012-08-06	6,644	$70.48	36,930	No	4	S	Direct
Common Stock	Disposition	2012-08-06	829	$71.87	36,101	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2012-08-06	9,333	$0.00	9,333	$35.18
Common Stock	Stock Option (right to Buy)	Disposition	2012-08-06	12,708	$0.00	12,708	$26.38

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
18,667		2021-03-31	No	4	M	Direct
51,792		2020-09-29	No	4	M	Direct

Footnotes

The shares were sold at prices between $70.35 and $70.69. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The shares were sold at prices between $70.454 and $70.49. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.
Twenty-Five percent of the shares subject to the option vest and become exercisable one year from the date of grant and vest and become exercisable at a rate of 1/48th per month thereafter.